3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Tuberous Sclerosis
3
Seizures
3
Sturge-Weber Syndrome
2
Nausea
2
Vomiting
1
Parasomnias
1
Pain
1
Neoplasms
1
Marijuana Abuse
1
Dysgeusia
1
Drug Resistant Epilepsy
1
Cognitive Dysfunction
1
Chemotherapy-Induced Peripheral Neuropathy
1
Cancer Pain
1
Cachexia
1
Breast Neoplasms
1
Behavior
1
Arthralgia
1
Appetitive Behavior
1
Anxiety Disorders
1
Interventions
Morphine
11
Oxycodone
8
Fentanyl
6
nabiximols
5
Methadone
4
Hydromorphone
4
Acetaminophen
3
Transcutaneous Electric Nerve Stimulation
2
Tapentadol
2
Naloxone
2
Lidocaine
2
Buprenorphine
2
Acupuncture Therapy
2
tanezumab
1
resiniferatoxin
1
oxycodone naloxone combination
1
fulranumab
1
cannabichromene
1
alvimopan
1
Water
1
Ultracet
1
Transcranial Direct Current Stimulation
1
Tramadol
1
Therapeutic Touch
1
Telemedicine
1
Tablets
1
Surveys and Questionnaires
1
Sugars
1
Radiotherapy, Intensity-Modulated
1
Radiosurgery
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Cancer Pain
×
Cannabidiol
×
Clear all
NCT06533657
2026-04-21
UTOPIA-1
ZYUS Life Sciences Inc.
Phase 2
Completed
11 enrolled